Dataset Information

Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

ABSTRACT: We present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. We identify a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at moderate disease, multiple unusual immune cell phenotypes emerge and amplify with increasing disease severity. We condensed over 120,000 immune features into a single axis to capture how different immune cell classes coordinate in response to SARS-CoV-2. This immune-response axis independently aligns with the major plasma composition changes, with clinical metrics of blood clotting, and with the sharp transition between mild and moderate disease. This study suggests that moderate disease may provide the most effective setting for therapeutic intervention.

SUBMITTER: Su Y

PROVIDER: S-EPMC7598382 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

Su Yapeng Y Chen Daniel D Yuan Dan D Lausted Christopher C Choi Jongchan J Dai Chengzhen L CL Voillet Valentin V Duvvuri Venkata R VR Scherler Kelsey K Troisch Pamela P Baloni Priyanka P Qin Guangrong G Smith Brett B Kornilov Sergey A SA Rostomily Clifford C Xu Alex A Li Jing J Dong Shen S Rothchild Alissa A Zhou Jing J Murray Kim K Edmark Rick R Hong Sunga S Heath John E JE Earls John J Zhang Rongyu R Xie Jingyi J Li Sarah S Roper Ryan R Jones Lesley L Zhou Yong Y Rowen Lee L Liu Rachel R Mackay Sean S O'Mahony D Shane DS Dale Christopher R CR Wallick Julie A JA Algren Heather A HA Zager Michael A MA Wei Wei W Price Nathan D ND Huang Sui S Subramanian Naeha N Wang Kai K Magis Andrew T AT Hadlock Jenn J JJ Hood Leroy L Aderem Alan A Bluestone Jeffrey A JA Lanier Lewis L LL Greenberg Philip D PD Gottardo Raphael R Davis Mark M MM Goldman Jason D JD Heath James R JR

Cell 20201028 6

We present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. We identify a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at m ...[more]

PMID: 33171100

Similar Datasets

Project description:BackgroundPatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications.MethodsIn this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19-related hospitalization or death from any cause by day 29.ResultsA total of 1035 patients underwent randomization and received an infusion of bamlanivimab-etesevimab or placebo. The mean (±SD) age of the patients was 53.8±16.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab-etesevimab group had a Covid-19-related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, -4.8 percentage points; 95% confidence interval [CI], -7.4 to -2.3; relative risk difference, 70%; P<0.001). No deaths occurred in the bamlanivimab-etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19-related. At day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than among those who received placebo (difference from placebo in the change from baseline, -1.20; 95% CI, -1.46 to -0.94; P<0.001).ConclusionsAmong high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19-related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).

Dataset Information

Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

Publications

Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets